Pseudomonas aeruginosa bacterial cell surface receptors

Pseudomonas aeruginosa bacterial cell surface receptors represent a heterogeneous group of molecules, including outer membrane proteins (OMPs), lipopolysaccharides (LPS), and specialized transport proteins like siderophore receptors (e.g., FpvA) (Frontiers in Microbiology, 2019). These receptors are essential for the pathogen's survival, facilitating nutrient uptake, environmental sensing, and adherence to host tissues via structures like Type IV pili and flagella (Journal of Bacteriology, 2021). In the context of disease, these surface components play a pivotal role in the formation of biofilms and the evasion of host immune responses, contributing significantly to chronic infections in cystic fibrosis and healthcare-associated pneumonia (Nature Reviews Microbiology, 2022). Therapeutic strategies targeting these receptors include the use of polymyxins, which disrupt the outer membrane by binding to LPS, and novel monoclonal antibodies like MedI3902 that target surface polysaccharides and protein secretion systems (Science Translational Medicine, 2017). Additionally, siderophore-antibiotic conjugates like cefiderocol exploit these receptors to bypass the outer membrane barrier, while small molecule inhibitors of lectins (LecA/LecB) are being explored to disrupt biofilm architecture (Chemical Communications, 2020). Targeting these receptors is a key strategy in treating multi-drug resistant Pseudomonas infections, although the high plasticity of the Pseudomonas genome allows for rapid modification of these surface targets, posing a significant challenge for long-term therapeutic efficacy.

Other names

Pseudomonas surface proteinsP. aeruginosa outer membrane receptorsPseudomonas cell surface componentsPseudomonas virulence factors

Drugs targeting these receptors typically act by disrupting the structural integrity of the outer membrane (e.g., polymyxins binding to LPS), utilizing siderophore transport systems for periplasmic entry (e.g., cefiderocol), or neutralizing surface-associated virulence factors and adhesins to prevent biofilm formation and host cell attachment (e.g., monoclonal antibodies).